Azithromycin Suspension Award
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-D-0010
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents2
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the exercise of Option 1 on contract SPE2D2-25-D-0010, pertaining to the supply of Azithromycin Suspension. This procurement activity is classified under NAICS code 325412, which covers Pharmaceutical Preparation Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on pharmaceuticals and drugs.
The primary objective of this contract is to ensure the continued availability and supply of Azithromycin Suspension, a critical pharmaceutical product, to meet the ongoing needs of the Department of Defense and its supported entities. The exercise of this contract option reflects the government’s intent to maintain a reliable source of this medication, supporting readiness and healthcare delivery for military personnel and associated beneficiaries.
The place of performance for this contract is specified as Laurelton, New York, United States. Contractors engaged in this effort are expected to have the capability to manufacture, package, and deliver pharmaceutical-grade Azithromycin Suspension in accordance with federal standards and DLA requirements. The scope of work likely includes adherence to stringent quality assurance protocols, regulatory compliance, and timely fulfillment of delivery schedules, although specific deliverable quantities and timelines are not detailed in the notice.
DLA Troop Support serves as the contracting entity, functioning as a federal office within the Defense Logistics Agency. The primary point of contact for this procurement is Kahaun Vicks, who can be reached at [email protected] or by phone at 215-737-0652. A secondary contact, Jason C. Wray, is also available at [email protected] or 215-737-0614, providing additional avenues for communication regarding contract administration or technical inquiries.
This award notice is currently active and was posted on June 4, 2026. Interested parties can access further details and any associated attachments via the official SAM.gov opportunity listing at https://sam.gov/opp/f444d2d3e1b44ac492478c6705397db8/view. The notice does not specify any set-aside requirements or special considerations, nor does it detail the procurement method or competition type, focusing solely on the exercise of an existing contract option.
Contractors evaluating this opportunity should note the ongoing nature of the requirement, the need for compliance with pharmaceutical manufacturing standards, and the importance of reliable supply chain management to support DLA’s mission. The contract’s core elements—pharmaceutical manufacturing, federal quality standards, and delivery to a specified location—are expected to remain constant throughout the contract lifecycle.